For decades, lung cancer has been the most common cause of cancer-related deaths worldwide. Approximately 1.6 million people die from lung cancer each year, and the 5-year survival rate is less than 17%. Therefore, it is necessary to design and develop new anti-lung cancer agents. In addition, metal-based agents offer potential advantages over the more common organic-based drugs, including available redox states, thermodynamics and kinetics characteristics, a wide range of coordination numbers and geometries, and intrinsic properties of the ligand itself and the metal ion. Therefore, medicinal metal-based agents offer additional opportunities to design anti-cancer agents not accessible to organic compounds.
In this Research Topic, we invite submissions of recent advances in metal-based agents to treat lung cancer. We intend to emphasize the importance of metal-based agents against lung cancer, ranging from the design and anti-lung cancer activity of metal-based agents to the anti-cancer mechanism of metal-based agents. We encourage researchers from medicinal chemistry, pharmacology, chemistry, biology, and nanotechnology interested in this topic to contribute research articles or review articles on metal-based drugs for the treatment of lung cancer.
This Research Topic welcomes Original Research, Mini Review, and Review articles. Potential subtopics include, but are not limited to:
• Design and activity evaluation of anti-lung cancer metal-based agents.
• Analysis of the mechanism of action of anti-lung cancer metal-based agents.
• Improvement and development of nanoformulations of metal-based agents for lung cancer treatment.
• Clinical application of anti-lung cancer metal-based agents.
• Research on metal-based agents in the diagnosis of lung cancer.
For decades, lung cancer has been the most common cause of cancer-related deaths worldwide. Approximately 1.6 million people die from lung cancer each year, and the 5-year survival rate is less than 17%. Therefore, it is necessary to design and develop new anti-lung cancer agents. In addition, metal-based agents offer potential advantages over the more common organic-based drugs, including available redox states, thermodynamics and kinetics characteristics, a wide range of coordination numbers and geometries, and intrinsic properties of the ligand itself and the metal ion. Therefore, medicinal metal-based agents offer additional opportunities to design anti-cancer agents not accessible to organic compounds.
In this Research Topic, we invite submissions of recent advances in metal-based agents to treat lung cancer. We intend to emphasize the importance of metal-based agents against lung cancer, ranging from the design and anti-lung cancer activity of metal-based agents to the anti-cancer mechanism of metal-based agents. We encourage researchers from medicinal chemistry, pharmacology, chemistry, biology, and nanotechnology interested in this topic to contribute research articles or review articles on metal-based drugs for the treatment of lung cancer.
This Research Topic welcomes Original Research, Mini Review, and Review articles. Potential subtopics include, but are not limited to:
• Design and activity evaluation of anti-lung cancer metal-based agents.
• Analysis of the mechanism of action of anti-lung cancer metal-based agents.
• Improvement and development of nanoformulations of metal-based agents for lung cancer treatment.
• Clinical application of anti-lung cancer metal-based agents.
• Research on metal-based agents in the diagnosis of lung cancer.
